AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05563714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation (CNNF)
Description: An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
Study NCT05563714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list control
Description: The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
Study NCT05227300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution
Description: Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
Study NCT05227300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: Septodont's standard formulation of 2% lidocaine with epinephrine
Study NCT05227300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: Septodont's standard formulation of 2% lidocaine with epinephrine
Study NCT06284577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain Probiotic
Description: Participants will recieve a multi-strain probiotic daily for 6 months
Study NCT06284577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo - maltodextrin
Description: Participants will recieve placebo/ maltodextri daily for 6 months
Study NCT06111274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib (ABSK021)
Description: The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
Study NCT05755152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyphenol-lecithin precipitate (PLP)
Description: Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
Study NCT05755152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control formulation
Description: Chewing gum made with material produced from conventional technology (e.g cranberry extract).
Study NCT01795274 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
Study NCT06295328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
Study NCT06295328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
Study NCT06295328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 245mg standard of care
Study NCT06295328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 245mg standard of care
Study NCT05233930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKR with augmented reality-based navigation system
Description: Surgery
Study NCT05233930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with traditional mechanically aligned technique
Description: As per local practice and standard guidelines.
Study NCT05217706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The treatment group will receive Ketamine 0.2mg/kg IV once
Study NCT05217706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: The placebo group will receive normal saline IV in a matched syringe
Study NCT03744663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone® SL
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
Study NCT03744663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade®
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of > 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
Study NCT06314880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
Study NCT06314880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
Study NCT04725019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation
Description: Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
Study NCT04725019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
Study NCT06261008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI group
Description: CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
Study NCT05653804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tele-visit
Description: The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
Study NCT06283277 — intervention group
Intervention type: DEVICE
Intervention: Obstetric Ultrasound
Description: Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
Study NCT05325762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
Study NCT05325762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
Study NCT05564442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% benzocaine gel
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study NCT05564442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electric nerve stimuli
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study NCT05564442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emla gel
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study NCT05564442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice application
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study NCT04746209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha/Beta T-cell and B-cell depleted HCT
Description: Device: Alpha/Beta T-cell and B-cell depletion
Study NCT04746209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
Study NCT06314880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Placebo control. 20 people/group.
Study NCT05325762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
Study NCT05115565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation) Application
Description: Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
Study NCT06170567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of puzzles on students' course success
Description: The effect of puzzles on students' course success
Study NCT04884763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
Description: Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Study NCT04884763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Description: Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Study NCT05178888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor
Study NCT05194878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapyI
Description: mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
Study NCT05194878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: Radical colectomy
Study NCT05194878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colectomy
Description: Radical colectomy
Study NCT05194878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
Study NCT06007131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study NCT05256134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered as per the dosing schedule described in the Arm description.
Study NCT05256134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the dosing schedule described in the Arm description.
Study NCT06438536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Social Cognitive Training
Description: Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
Study NCT05152251 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
Study NCT06440603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System
Study NCT05842486 — intervention group
Intervention type: OTHER
Intervention: Anti-C5 antibody treatment
Description: Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
Study NCT05945498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB/Flu-05E vaccine
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
Study NCT05945498 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single intranasal injection of placebo buffer solution
Study NCT05508646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Description: The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
Study NCT05508646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized music CD
Description: Participants will receive a personalized music CD that they keep and can listen to as they wish.
Study NCT05634473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: Cholinergic agonists
Study NCT04780529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gucy2c cart cells
Description: Patients with advanced malignant gastrointestinal tumors were injected with CART cells
Study NCT05065801 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GABRINOX
Description: Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX
Study NCT05065801 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: Patients in this arm received reatment: 3 cycles of FOLFIRINOX
Study NCT05178888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4 and 6 inhibitor
Study NCT04746963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.1 mg
Description: Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
Study NCT06163196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
Study NCT06163196 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupressure
Description: Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
Study NCT05853588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Description: On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
Study NCT05197465 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
Study NCT03773003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus
Study NCT05248555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Testing
Description: Participants will be offered finger-stick point-of-care testing for HCV
Study NCT03773003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking to verum, containing corn starch.
Study NCT05364710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transfer factor from colostrum ultrafiltrate
Description: Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
Study NCT05871580 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency laser activated photobiomodulation
Description: Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point.
Study NCT05871580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency laser photobiomodulation inactive
Description: The same protocol as the activated group
Study NCT05988918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: 160 mg, PO, Once daily 5 days on and 2 days off
Study NCT04303975 — intervention group
Intervention type: OTHER
Intervention: clinical measurements
Description: Only clinical parameters were recorded, no intervention was made.
Study NCT06332586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diversified teaching
Description: Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
Study NCT04853914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: HIFU treatment of Benign Prostatic Hyperplasia
Study NCT06295900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 1 Group
Description: 20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.